157 related articles for article (PubMed ID: 19924443)
1. XPC gene variants: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy.
Gangwar R; Mandhani A; Mittal RD
J Cancer Res Clin Oncol; 2010 May; 136(5):779-86. PubMed ID: 19924443
[TBL] [Abstract][Full Text] [Related]
2. Interactions between cigarette smoking and XPC-PAT genetic polymorphism enhance bladder cancer risk.
Liu Y; Wang H; Lin T; Wei Q; Zhi Y; Yuan F; Song B; Yang J; Chen Z
Oncol Rep; 2012 Jul; 28(1):337-45. PubMed ID: 22505326
[TBL] [Abstract][Full Text] [Related]
3. The polyAT, intronic IVS11-6 and Lys939Gln XPC polymorphisms are not associated with transitional cell carcinoma of the bladder.
Sak SC; Barrett JH; Paul AB; Bishop DT; Kiltie AE
Br J Cancer; 2005 Jun; 92(12):2262-5. PubMed ID: 15886698
[TBL] [Abstract][Full Text] [Related]
4. Association of XPC polymorphisms with susceptibility and clinical outcome to chemotherapy in breast cancer patients.
Yang X; Liu D; Wu H; Kang H; Pang H; Huang D; Sha X; Wang E; Wang Z; Wei M
Cancer Sci; 2012 Jul; 103(7):1207-14. PubMed ID: 22519360
[TBL] [Abstract][Full Text] [Related]
5. Genetic variants of DNA repair gene XPC modulating susceptibility to cervical cancer in North India.
Gangwar R; Mittal B; Srivastava S; Singh H; Mittal RD
Oncol Res; 2010; 18(7):329-35. PubMed ID: 20377134
[TBL] [Abstract][Full Text] [Related]
6. A33512C and Intronic Poly(AT) Insertion/Deletion (PAT-/+) Polymorphisms of the XPC Gene and Their Association With the Risk of Breast Cancer.
Qazvini MG; Salehi Z; Mashayekhi F; Saedi HS
Clin Breast Cancer; 2020 Dec; 20(6):e771-e777. PubMed ID: 32682659
[TBL] [Abstract][Full Text] [Related]
7. [Correlation of XPC Ala499Val and Lys939Gln polymorphisms to risks of esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma].
Zhou RM; Li Y; Wang N; Zhang XJ; Dong XJ; Guo W
Ai Zheng; 2006 Sep; 25(9):1113-9. PubMed ID: 16965652
[TBL] [Abstract][Full Text] [Related]
8. XRCC1 codon 399 mutant allele: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy.
Mittal RD; Singh R; Manchanda PK; Ahirwar D; Gangwar R; Kesarwani P; Mandhani A
Cancer Biol Ther; 2008 May; 7(5):645-50. PubMed ID: 18364571
[TBL] [Abstract][Full Text] [Related]
9. IL-8 -251 T > A polymorphism is associated with bladder cancer susceptibility and outcome after BCG immunotherapy in a northern Indian cohort.
Ahirwar DK; Mandhani A; Mittal RD
Arch Med Res; 2010 Feb; 41(2):97-103. PubMed ID: 20470938
[TBL] [Abstract][Full Text] [Related]
10. An association between XPC Lys939Gln polymorphism and the risk of bladder cancer: a meta-analysis.
Zhang Y; Wang X; Zhang W; Gong S
Tumour Biol; 2013 Apr; 34(2):973-82. PubMed ID: 23269608
[TBL] [Abstract][Full Text] [Related]
11. Caspase 9 and caspase 8 gene polymorphisms and susceptibility to bladder cancer in north Indian population.
Gangwar R; Mandhani A; Mittal RD
Ann Surg Oncol; 2009 Jul; 16(7):2028-34. PubMed ID: 19412632
[TBL] [Abstract][Full Text] [Related]
12. Population study of genetic polymorphisms and superficial bladder cancer risk in Han-Chinese smokers in Shanghai.
Wen H; Ding Q; Fang ZJ; Xia GW; Fang J
Int Urol Nephrol; 2009 Dec; 41(4):855-64. PubMed ID: 19350405
[TBL] [Abstract][Full Text] [Related]
13. The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer.
Kang HW; Tchey DU; Yan C; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YH; Kim IY; Kim WJ
Urol Oncol; 2014 May; 32(4):458-65. PubMed ID: 24411789
[TBL] [Abstract][Full Text] [Related]
14. DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy.
Liu D; Wu HZ; Zhang YN; Kang H; Sun MJ; Wang EH; Yang XL; Lian MQ; Yu ZJ; Zhao L; Olopade OI; Wei MJ
Mol Carcinog; 2012 Oct; 51 Suppl 1():E83-93. PubMed ID: 22213216
[TBL] [Abstract][Full Text] [Related]
15. Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer.
Zhu Y; Lai M; Yang H; Lin J; Huang M; Grossman HB; Dinney CP; Wu X
Carcinogenesis; 2007 Mar; 28(3):698-703. PubMed ID: 17052994
[TBL] [Abstract][Full Text] [Related]
16. The association between XPC Lys939Gln gene polymorphism and urinary bladder cancer susceptibility: a systematic review and meta-analysis.
Dou K; Xu Q; Han X
Diagn Pathol; 2013 Jul; 8():112. PubMed ID: 23819639
[TBL] [Abstract][Full Text] [Related]
17. Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India.
Gangawar R; Ahirwar D; Mandhani A; Mittal RD
Med Oncol; 2010 Jun; 27(2):159-66. PubMed ID: 19242824
[TBL] [Abstract][Full Text] [Related]
18. Association of DNA repair gene XPC Ala499Val (rs2228000 C>T) and Lys939Gln (rs2228001 A>C) polymorphisms with the risk of chronic myeloid leukemia: A case-control study in a South Indian population.
Lakkireddy S; Aula S; Kapley A; Gundeti S; Kutala VK; Jamil K
J Gene Med; 2021 Jul; 23(7):e3339. PubMed ID: 33829606
[TBL] [Abstract][Full Text] [Related]
19. Association of tumour necrosis factor-alpha gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette-Guérin immunotherapy.
Ahirwar DK; Mandhani A; Dharaskar A; Kesarwani P; Mittal RD
BJU Int; 2009 Sep; 104(6):867-73. PubMed ID: 19338536
[TBL] [Abstract][Full Text] [Related]
20. Association of single nucleotide polymorphisms in promoter of matrix metalloproteinase-2, 8 genes with bladder cancer risk in Northern India.
Srivastava P; Kapoor R; Mittal RD
Urol Oncol; 2013 Feb; 31(2):247-54. PubMed ID: 21784671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
